1. Clinical & Scientific Overview
Atorvastatin Calcium (TIP-MED-000016, Reference Code [3.16]) is classified under
Cardiovascular & Antithrombotic Medicines (Ch 03) as a HMG-CoA Reductase Inhibitor (Lipophilic Statin); Lipid-Lowering & Plaque-Stabilising Agent.
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug • NLEM 2022 Core Essential Medicine.
Representative Indian Market Examples (Edition 2.7 Ch 03 [3.16], p. 28): Atorva (Zydus), Storvas (Sun Pharma), Lipitor (Pfizer), Tonact (Lupin), Lipikind (Mankind), Aztor (Sun) — Strengths & Forms: Oral Film-Coated Tablets: 5 mg, 10 mg, 20 mg, 40 mg, 80 mg
Oral Film-Coated Tablets: 5 mg, 10 mg, 20 mg, 40 mg, 80 mg
3. Mechanism of Action & Pharmacodynamics
Competitively inhibits 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme converting HMG-CoA to mevalonate in hepatic cholesterol synthesis. Depletion of intracellular hepatocyte sterols activates SREBP-2, upregulating hepatic surface LDL receptors and lowering plasma LDL-C by 35%–55%.
4. Therapeutic Indications & Evidence-Supported Uses
- Primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD, post-MI, post-PCI, stroke)
- Primary hypercholesterolaemia (heterozygous/homozygous familial) and mixed dyslipidaemia
- Diabetic dyslipidaemia in adults aged 40–75 years
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Moderate-intensity: 10–20 mg orally once daily. High-intensity (ACS / secondary prevention): 40–80 mg orally once daily at any time of day.
Administration & Meal Timing: Oral; can be taken at any time of day (morning or bedtime) with or without food due to its 20–30 hr active metabolite half-life.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Contraindicated in active acute liver disease or unexplained persistent transaminase elevations (>3x ULN).
No dose adjustment required in chronic kidney disease (<2% renal excretion); preferred statin alongside Rosuvastatin in CKD.
Contraindicated in active acute liver disease or unexplained persistent transaminase elevations (>3x ULN).
7. Contraindications, Precautions & High-Risk Warnings
- Active liver disease or unexplained persistent serum transaminase elevation >3x ULN
- Pregnancy and breastfeeding
- Concomitant strong CYP3A4 / OATP1B1 inhibitors (Cyclosporine, Gemfibrozil, Tipranavir/Ritonavir)
Key Clinical Precautions: Contraindicated in active acute liver disease or unexplained persistent transaminase elevations (>3x ULN).
8. Adverse Effects Profile
- Statin-associated muscle symptoms (myalgia, cramps; rare CPK >10x ULN myopathy or rhabdomyolysis <0.1%)
- Asymptomatic reversible elevation of hepatic transaminases (ALT/AST)
- Modest dose-dependent increase in incident Type 2 Diabetes / HbA1c (~0.1–0.2%; CV benefit outweighs risk)
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Clarithromycin, Itraconazole, Protease Inhibitors (CYP3A4 inhibition): markedly increases Atorvastatin AUC and rhabdomyolysis risk (limit dose <=20 mg)
- Gemfibrozil (OATP1B1 & glucuronidation inhibition): contraindicated due to severe myopathy risk (Fenofibrate preferred if fibrate required)
- Grapefruit juice (>1.2 L/day): inhibits enteric CYP3A4 and elevates statin exposure
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- May be taken at any consistent time of day (unlike short-acting Simvastatin which must be taken at night).
- Report unexplained severe muscle pain, tenderness, weakness, or dark cola-coloured urine promptly.
- Continue diet and physical activity alongside statin therapy.
Storage, Stability & Dispensing Safeguards: Store below 25–30°C protected from moisture.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2026) • NLEM 2022 (MoHFW) • CDSCO Approved Prescribing Information
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.